Rhinology
Head-to-Head Trials of Biologics in CRSwNP
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.
MD, PhD
Sietze Reitsma
Related resources
Learning objectives
- To recognize the clinical benefits of dupilumab in improving nasal polyp size and smell function in patients with CRSwNP and coexisting asthma
- To understand the importance of individualized biologic therapy selection based on patient response and disease severity, using evidence from trials like EVEREST and TORNADO
Description
This video highlights findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma, with similar safety profiles. It also introduces the ongoing TORNADO study in Denmark, comparing dupilumab and mepolizumab in biologic-eligible patients, with treatment decisions made after 24 weeks based on clinical response.
Tags
MAT-GLB-2506246 - 1.0 - 10/2025
About this expert
Rhinology
Sietze Reitsma
MD, PhD
ENT and Rhinologist at the University Medical Centres in Amsterdam | Professor at the Department of Otorhinolaryngology and Head and Neck Surgery | University of Amsterdam
See author’s profile